vs

Side-by-side financial comparison of COFFEE HOLDING CO INC (JVA) and MEDIFAST INC (MED). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $27.7M, roughly 2.7× COFFEE HOLDING CO INC). On growth, COFFEE HOLDING CO INC posted the faster year-over-year revenue change (30.8% vs -36.9%). COFFEE HOLDING CO INC produced more free cash flow last quarter ($265.4K vs $-6.6M). Over the past eight quarters, COFFEE HOLDING CO INC's revenue compounded faster (19.2% CAGR vs -34.4%).

Black Rifle Coffee Company (BRCC) is a coffee company based in Salt Lake City, Utah, United States. Founded in 2014 by former U.S. Army Green Beret Evan Hafer, it gained national attention in 2017 after pledging to hire 10,000 veterans in response to Starbucks's pledge to hire 10,000 refugees.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

JVA vs MED — Head-to-Head

Bigger by revenue
MED
MED
2.7× larger
MED
$75.1M
$27.7M
JVA
Growing faster (revenue YoY)
JVA
JVA
+67.7% gap
JVA
30.8%
-36.9%
MED
More free cash flow
JVA
JVA
$6.9M more FCF
JVA
$265.4K
$-6.6M
MED
Faster 2-yr revenue CAGR
JVA
JVA
Annualised
JVA
19.2%
-34.4%
MED

Income Statement — Q4 2025 vs Q4 2025

Metric
JVA
JVA
MED
MED
Revenue
$27.7M
$75.1M
Net Profit
$811.5K
Gross Margin
8.5%
69.4%
Operating Margin
2.8%
-10.4%
Net Margin
2.9%
Revenue YoY
30.8%
-36.9%
Net Profit YoY
-35.7%
EPS (diluted)
$0.15
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
JVA
JVA
MED
MED
Q4 25
$27.7M
$75.1M
Q3 25
$23.9M
$89.4M
Q2 25
$23.3M
$105.6M
Q1 25
$21.3M
$115.7M
Q4 24
$21.2M
$119.0M
Q3 24
$18.8M
$140.2M
Q2 24
$19.0M
$168.6M
Q1 24
$19.5M
$174.7M
Net Profit
JVA
JVA
MED
MED
Q4 25
$811.5K
Q3 25
$-1.2M
$-2.3M
Q2 25
$644.1K
$2.5M
Q1 25
$1.2M
$-772.0K
Q4 24
$1.3M
Q3 24
$626.8K
$1.1M
Q2 24
$-21.8K
$-8.2M
Q1 24
$351.0K
$8.3M
Gross Margin
JVA
JVA
MED
MED
Q4 25
8.5%
69.4%
Q3 25
12.2%
69.5%
Q2 25
18.9%
72.6%
Q1 25
26.9%
72.8%
Q4 24
23.2%
74.1%
Q3 24
20.9%
75.4%
Q2 24
19.5%
73.2%
Q1 24
17.8%
72.8%
Operating Margin
JVA
JVA
MED
MED
Q4 25
2.8%
-10.4%
Q3 25
-4.6%
-4.6%
Q2 25
3.8%
-1.0%
Q1 25
7.5%
-1.1%
Q4 24
8.0%
0.6%
Q3 24
3.8%
1.5%
Q2 24
-0.4%
-4.7%
Q1 24
3.2%
4.5%
Net Margin
JVA
JVA
MED
MED
Q4 25
2.9%
Q3 25
-5.0%
-2.5%
Q2 25
2.8%
2.3%
Q1 25
5.4%
-0.7%
Q4 24
5.9%
Q3 24
3.3%
0.8%
Q2 24
-0.1%
-4.8%
Q1 24
1.8%
4.8%
EPS (diluted)
JVA
JVA
MED
MED
Q4 25
$0.15
$-1.64
Q3 25
$-0.21
$-0.21
Q2 25
$0.11
$0.22
Q1 25
$0.20
$-0.07
Q4 24
$0.22
$0.08
Q3 24
$0.11
$0.10
Q2 24
$0.00
$-0.75
Q1 24
$0.06
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
JVA
JVA
MED
MED
Cash + ST InvestmentsLiquidity on hand
$701.9K
$167.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$27.6M
$198.9M
Total Assets
$42.0M
$248.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
JVA
JVA
MED
MED
Q4 25
$701.9K
$167.3M
Q3 25
$979.8K
$173.5M
Q2 25
$1.8M
$162.7M
Q1 25
$2.4M
$164.6M
Q4 24
$1.4M
$162.3M
Q3 24
$3.1M
$170.0M
Q2 24
$2.4M
$163.5M
Q1 24
$2.4M
$156.4M
Stockholders' Equity
JVA
JVA
MED
MED
Q4 25
$27.6M
$198.9M
Q3 25
$26.8M
$214.7M
Q2 25
$28.0M
$216.0M
Q1 25
$27.3M
$211.0M
Q4 24
$26.2M
$210.1M
Q3 24
$24.9M
$207.3M
Q2 24
$24.3M
$205.3M
Q1 24
$24.3M
$211.0M
Total Assets
JVA
JVA
MED
MED
Q4 25
$42.0M
$248.0M
Q3 25
$45.9M
$268.2M
Q2 25
$39.7M
$269.3M
Q1 25
$38.9M
$280.0M
Q4 24
$34.0M
$284.2M
Q3 24
$33.1M
$291.2M
Q2 24
$34.9M
$293.5M
Q1 24
$37.6M
$302.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
JVA
JVA
MED
MED
Operating Cash FlowLast quarter
$377.7K
$-5.3M
Free Cash FlowOCF − Capex
$265.4K
$-6.6M
FCF MarginFCF / Revenue
1.0%
-8.8%
Capex IntensityCapex / Revenue
0.4%
1.8%
Cash ConversionOCF / Net Profit
0.47×
TTM Free Cash FlowTrailing 4 quarters
$-5.2M
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
JVA
JVA
MED
MED
Q4 25
$377.7K
$-5.3M
Q3 25
$-3.8M
$12.1M
Q2 25
$-1.2M
$-3.4M
Q1 25
$-401.9K
$3.4M
Q4 24
$222.0K
$-4.9M
Q3 24
$1.8M
$9.1M
Q2 24
$-1.2M
$13.1M
Q1 24
$4.6M
$7.3M
Free Cash Flow
JVA
JVA
MED
MED
Q4 25
$265.4K
$-6.6M
Q3 25
$-3.9M
$10.8M
Q2 25
$-1.2M
$-4.8M
Q1 25
$-419.8K
$1.9M
Q4 24
$-7.2M
Q3 24
$1.8M
$7.7M
Q2 24
$11.1M
Q1 24
$5.4M
FCF Margin
JVA
JVA
MED
MED
Q4 25
1.0%
-8.8%
Q3 25
-16.3%
12.0%
Q2 25
-5.0%
-4.5%
Q1 25
-2.0%
1.6%
Q4 24
-6.1%
Q3 24
9.4%
5.5%
Q2 24
6.6%
Q1 24
3.1%
Capex Intensity
JVA
JVA
MED
MED
Q4 25
0.4%
1.8%
Q3 25
0.2%
1.5%
Q2 25
0.1%
1.3%
Q1 25
0.1%
1.3%
Q4 24
1.9%
Q3 24
0.2%
1.0%
Q2 24
1.1%
Q1 24
1.1%
Cash Conversion
JVA
JVA
MED
MED
Q4 25
0.47×
Q3 25
Q2 25
-1.79×
-1.36×
Q1 25
-0.35×
Q4 24
0.18×
Q3 24
2.90×
8.04×
Q2 24
Q1 24
13.09×
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons